Company profile
ProPhase Labs, Inc.
NASDAQ: PRPH · Healthcare · Medical - Pharmaceuticals
#718 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
38DFH 34DQ 49GM 18SS 53
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ filing timeliness, return on equity
Methodology →Revenue TTM
$3.4M
Rev growth YoY (TTM)
-25.7%
Net income (FY)
-$14.7M
Employees
19
as of 2026-08-27
Market cap
$323.8k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.3M$4.3M2025
Net income-$14.7M-$14.7M2025
Operating income-$18.0M-$18.0M2025
Total assets$59.9M$59.9M2025
Liabilities$56.4M$56.4M2025
Equity$3.5M$3.5M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Consumer Products100%
By geography
Not disclosed.
The read
What is ProPhase Labs, Inc.’s revenue?
ProPhase Labs, Inc. booked $4.3M in FY2025 revenue, contracting 36% year over year — slower than 78% of Healthcare companies we track, at a -339.3% net margin.
Peers · Healthcare
Ocugen, Inc.44DLift & Co. Corp.——Arrayit Corporation——Comprehensive Healthcare Systems, Inc.42DInsight Molecular Diagnostics Inc.37DHemagen Diagnostics, Inc.——Neighbors
Nassau →Key facts
CEOTed William Karkus
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersGarden City, NY
ExchangeNASDAQ: PRPH
Employees19
IPO date1994-04-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.